769 results about "Sustained Release Tablet" patented technology

The sustained release tablet of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) which is disclosed permits twice daily administration of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) to treat humans with Parkinson's disease.

A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises an active pharmaceutical agent having solubility not less than about 10 mg/ml, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm⁻² at a solid fraction representative of the tablet.

A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm⁻² at a solid fraction representative of the tablet.

The invention discloses a colchicine bilayer sustained-release tablet which comprises a quick release layer and a sustained-release layer, wherein the quick release layer mainly consists of colchicine, a disintegrant, a filler, a lubricant and an adhesive; the sustained-release tablet mainly consists of colchicine, a sustained-release matrix, a retarding agent, a filler and an adhesive; the weight ratio of the colchicine in the quick release layer to the colchicine in the sustained-release layer is (0.25-0.42) : 1; and the weight ratio of the quick release layer to the sustained-release layer is 1: 2 to 1: 4. The invention also discloses a method for preparing the colchicine bilayer sustained-release tablet. The colchicine bilayer sustained-release tablet releases the drugs through the quick release layer to quickly achieve the effective blood drug concentration, slowly releases the drugs through the sustained-release layer to exert and sustain the stable and uniform effective blood drug concentration, reduces the drug taking times and lightens the toxic or side function.

The invention provides a ticagrelor sustained-release tablet system and a preparation method of the ticagrelor sustained-release tablet system. The preparation method comprises the following steps of: firstly uniformly mixing 10-60% of ticagrelor, 5-60% of a filler and 5-60% of high molecular polymer in percentage by weight, adding a granulating solution to granulate; fully drying the obtained granules at a temperature of 50-60 DEG C, uniformly mixing the sieved granules with 0.25-10% of a lubricant and/or 0-10% of a flow aid, carrying out tabletting to obtain the ticagrelor matrix type sustained-release tablets, wherein the granulating solution is preferably water, an alcohol-water solution or absolute ethyl alcohol; the granule size of the ticagrelor is below 100 micrometers; and the content of the ticagrelor is 50-300mg in the preparation process. The ticagrelor matrix type sustained-release tablet system provided by the invention has the advantages that a patient can take the ticagrelor once a day to ensure that the drug dependence of the patient can be improved and the risk of myocardial infarction or apoplexy caused by acute thrombosis due to a dose of the ticagrelor missing of the patient is reduced.

The present invention relates to sustained release oral dosage forms of gabapentin and at least one rate controlling polymer, and a process for the preparation of the sustained release oral dosage forms, and a process for the preparation thereof. The sustained release tablet includes gabapentin or a pharmaceutically acceptable salt or hydrates thereof and at least one rate-controlling polymer such that the tablet provides therapeutically effective plasma levels of gabapentin for a period of up to about 12 hours.

The invention discloses a lovastatin-containing enteric coated sustained-release pellet capsule and a preparation method thereof. The lovastatin-containing enteric coated sustained-release pellet capsule comprises two parts, namely, an enteric coated sustained-release pellet and a hollow capsule, wherein the enteric coated sustained-release pellet comprises 55-86% of medicine-containing pellet core, 2-5% of isolation coating layer, 2-15% of a sustained-release coating layer and 10-25% of enteric-coated coating layer by weight. The prepared lovastatin enteric coated sustained-release pellet capsule is uniform in granule size and stable in medicine release; the medicine is not released in gastric acid but is slowly and constantly released in intestinal tracts and livers, has the characteristic of targeted medicine release, is small in irritation to gastrointestinal tracts, and can reduce the toxic and side effects of the medicine and reduce the number of the medicine administrations, so that the compliance of patients is improved; and meanwhile as the enteric coated sustained-release pellet preparation is composed of hundreds of pellets of uniform granule sizes, the sudden release of the whole preparation is not caused by the breakage of individual pellets, so that the medicine is safer than a sustained-release tablet, smaller in irritation to gastrointestinal tracts and more stable in blood concentration, and the clinical effectiveness and security are effectively improved.

The invention relates to a double-layer sustained release tablet for supplementing iron, the double-layer sustained release tablet consists of a sustained release layer and a quick release layer laminating with each other at the weight ratio of 1:0.25-1:4; the sustained release layer consists of an iron-containing compound, a sustained release framework, an adhesive, a lubricant and a filler; the quick release layer consists of a traditional Chinese medicine for enriching the blood and/or invigorating vital energy, a filler, a disintegrating agent, an adhesive and a lubricant; the quick release layer can also be added with vitamins. In the double-layer sustained release tablet, by arranging the iron-containing compound in the sustained release layer and the traditional Chinese medicine in the quick release layer, the iron element is released slowly and uniformly, which increases the absorption rate, avoids gastrointestinal reaction caused by high-content iron; meanwhile the double-layer sustained release tablet supplements iron element and the traditional Chinese medicine which has the functions of enriching the blood and invigorating vital energy, thus fully improving the nutritional status caused by iron deficiency anemia and improving iron supplementing effect.

The invention relates to a preparation method of an enteric-coated sustained-release preparation, in particular to a preparation method of an aspirin enteric-coated sustained-release preparation. According to the preparation method, a prepared aspirin sustained-release tablet is used as a core tablet, and an enteric coating is packaged on the outer layer of the core tablet. In order to prevent aspirin in the core tablet from interacting with an enteric-coated material, an isolating layer can be packaged between the core tablet and the enteric coating. After the aspirin is prepared into the enteric-coated sustained-release preparation provided by the invention, the aspirin is not released or a little aspirin is released in a stomach, the release time in intestines is greatly extended, the phenomena of violent disintegration and dissolution do not occur in the intestines, the aspirin is released more slowly, the bioavailability is greatly increased, the degradation reaction of the aspirin in water is avoided, the frequency of administration is lower, and the compliance of a patient is improved.

The invention discloses a sustained release tablet of a quetiapine fumarate composition, comprising the following components in percentage by weight: 25 to 40% of quetiapine fumarate, 2 to 8% of organic acid salt, 5 to 30% of a sustained release material and the balance of other pharmaceutical adjuvants, wherein the sustained release material is K type hydroxypropyl methylcellulose. The sustained release material is the K type hydroxypropyl methylcellulose and the organic acid salt is added, therefore, a stable sustained release skeleton can be formed by few sustained release materials, the raw material can be saved, the weight of unit preparation can be reduced, and the problem of difficulty in swallowing caused by large size of the preparation can be released and/or solved; the hydroxypropyl methylcellulose with different viscosities are used as the material of the skeleton so that the preparation can reach formulated sustained release effects and has the characteristics of strong controllability and stability in storage. By use of the preparation method capable of granulating in one step, the operation is simplified and the production efficiency can be improved.

The invention relates to a medicinal composition containing ibuprofen sodium salt, which is prepared by taking ibuprofen sodium salt and other one or a plurality of medicinal components as active ingredients, and combing the active ingredients with pharmaceutically appropriate auxiliary materials. The medicinal composition can be made into oral preparations, including conventional tablets, dispersible tablets, sustained release tablets, capsules, sustained release capsules, soft capsules, particles, dry suspension, suspension and the like, and used for symptomatic treatment of being antipyretic, antiphlogistic, analgesic and anti-allergic, and improving sleeping.

The invention provides a nifedipine sustained-release tablet which contains a physiological effective dose of nifedipine and release blocker and a pharmaceutically acceptable excipient, wherein the nifedipine is dispersed in the release blocker; the release blocker is selected from macromolecular substances which can be swelled in water, such as hydroxypropyl methyl cellulose, sodium alginate, carboxymethyl cellulose, methyl cellulose and xanthan gum, and the amount of the used release blocker is 5-30 percent of the weight of the sustained-release tablet; and the nifedipine sustained-release tablet contains 15-30mg of nifedipine and also contains several of filler, a disintegrating agent, a surfactant, an adhesive, a lubricant and a glidant as the excipient. The nifedipine sustained-release tablet can be used for treating hypertension and angina pectoris.

The invention discloses a merariveron sustained-release tablet and a preparation method thereof. The merariveron sustained-release tablet is prepared from the following raw materials in percentage by weight: 5- 20% of merariveron, 10-70% of a skeleton material, 1- 5% of an antioxidant, 0.1-5% of a lubricant, 0-70% of a filler and a proper amount of an adhesive. The merariveron sustained-release tablet adopts a film coating, and thus the stability of the merariveron sustained-release tablet is improved. The sustained-release materials in the merariveron sustained-release tablet reduce influences, on release, of different PH valves. The influences, on the absorption of the merariveron sustained-release tablet, of food, are reduced, long-time stable effective drug concentration is kept, and thus the curative effect of the merariveron sustained-release tablet is improved. A patient only needs to take the merariveron sustained-release tablet once a day; the compliance of the patient is improved.

The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixtures thereof, and (3) a swelling agent to form a sustained release composition for extended release of the nicotinic acid or nicotinic acid compound or mixtures thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a composition for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl methylcellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an HMG-CoA reductase inhibitor in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compounds to provoke flushing reactions in individuals.

The invention discloses a mosapride citrate sustained-release tablet. The mosapride citrate sustained-release tablet comprises mosapride citrate, slow-release materials, a diluent, an adhesive, a lubricant and a coating material. A release degree of the mosapride citrate sustained-release tablet has good repeatability, regardless of being detected in an experiment or in mass production. After being subjected to stability monitoring for 6 months, the mosapride citrate sustained-release tablet still has an almost changeless release degree.

The invention provides a Metformin Hydrochloride slow release tablet and process for preparation, wherein the slow release tablet comprises metformin hydrochloride 46.5-70%, hydroxypropylcellulose 13.5-33.0%, micronization ethyl cellulose 10.0-14.0%, filling agent 1.3%-9.4%, and lubricating agent 1.2-1,5%. The preparation process comprises processing the prescribed raw material of metformin hydrochloride, cellulose glycollic ether, and the filling agent through the conventional tablet production process of granulation, drying, granulating, charging micronization ethyl cellulose, mixing homogenously with lubricant and tabletting.

A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described.

The invention relates to a preparation method of a clonidine hydrochloride sustained-release tablet. The preparation method comprises the steps of dissolving a clonidine hydrochloride raw material into a proper amount of wetting agent by using a solvent dispersion method to prepare a solution containing 10-28.57mg/ml clonidine; adding the solution into a granulation pan filled with a filling agent and a binder at constant speed of 5-40ml/min to granulate; drying the prepared granules, screening by using a 50-100-mesh sieve, mixing the granules, a framework material, a flow aid and a lubricating agent, and tabletting to obtain the clonidine hydrochloride sustained-release tablet. By using the preparation method, the problem of non-uniform content generated in a preparation process of the clonidine hydrochloride sustained-release tablet can be effectively solved, the prepared clonidine hydrochloride sustained-release tablet is uniform in content, and the release behavior is in accord with the sustained-release characteristic. All process parameters in the preparation method can be correspondingly amplified according to the industrial production scale, so that the requirement for large-scale industrial production can be met.

The invention belongs to the field of pharmaceutical preparations, more specifically relates to a seroquel sustained release tablet and a preparation method thereof. The sustained release tablet of the invention comprises 5%-50% of sustained release framework material with pH-dependent solubility according to weight percentage, and preferably comprises 15%-35% of the sustained release framework material with the pH-dependent solubility. The seroquel sustained release tablet prepared by the invention runs in the gastrointestinal tract by imitating sustained release and controlled release agents, the in vitro release rate thereof is determined, which proves that the sustained seroquel release tablet can continuously release for 6-24 hours. The seroquel sustained release tablet of the invention reduces dosage of sustained release material based on good sustained release performance and facilitates the administration of patients. The seroquel sustained release tablet of the invention has simple technology and is good for large-scale industrialized production at the same time.